S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:AURA

Aura Biosciences (AURA) Stock Price, News & Analysis

$7.70
+0.07 (+0.92%)
(As of 03/27/2024 ET)
Today's Range
$7.60
$8.07
50-Day Range
$7.09
$9.24
52-Week Range
$5.99
$13.50
Volume
140,008 shs
Average Volume
182,807 shs
Market Capitalization
$294.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

Aura Biosciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
172.7% Upside
$21.00 Price Target
Short Interest
Bearish
7.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.65mentions of Aura Biosciences in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$171,610 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.80) to ($1.82) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.39 out of 5 stars

Medical Sector

706th out of 939 stocks

Biological Products, Except Diagnostic Industry

117th out of 154 stocks

AURA stock logo

About Aura Biosciences Stock (NASDAQ:AURA)

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology. It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial. The company also develops AU-011 for additional ocular oncology indications, including choroidal metastases and is in Phase 2 dose-escalation trial. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

AURA Stock Price History

AURA Stock News Headlines

Recap: Aura Biosciences Q4 Earnings
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
BTIG Reaffirms Their Buy Rating on Aura Biosciences Inc (AURA)
David Johnson Bought 232% More Shares In Aura Biosciences
Aura Biosciences Prices Public Offering Of 11 Mln Shares Of At $9.00/shr
Aura Biosciences Inc AURA
See More Headlines
Receive AURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aura Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/15/2023
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AURA
Fax
N/A
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.00
High Stock Price Target
$23.00
Low Stock Price Target
$19.00
Potential Upside/Downside
+172.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-58,760,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.67 per share

Miscellaneous

Free Float
36,003,000
Market Cap
$294.60 million
Optionable
Not Optionable
Beta
0.40
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Elisabet de los Pinos Ph.D. (Age 51)
    Founder, CEO, President & Director
    Comp: $795.3k
  • Ms. Julie B. Feder (Age 54)
    CFO, Secretary & Treasurer
    Comp: $505.45k
  • Dr. Mark Plavsic D.V.M. (Age 63)
    Ph.D., Chief Technology Officer
  • Mr. Patrick Nealon
    Senior Vice President of Clinical Development Operations
  • Dr. Bruce Brown M.D.
    Senior VP & Therapeutic Area Head of Urologic Oncology
  • Dr. Anthony Daniels M.D.
    Therapeutic Area Head of Ocular Oncology
  • Dr. Richard Mountfield Ph.D.
    Senior Vice President of Regulatory Affairs & Quality
  • Dr. Jill Hopkins M.D.
    Chief Medical Officer & President of Research and Development

AURA Stock Analysis - Frequently Asked Questions

Should I buy or sell Aura Biosciences stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aura Biosciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AURA shares.
View AURA analyst ratings
or view top-rated stocks.

What is Aura Biosciences' stock price target for 2024?

3 analysts have issued 12-month target prices for Aura Biosciences' shares. Their AURA share price targets range from $19.00 to $23.00. On average, they expect the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 172.7% from the stock's current price.
View analysts price targets for AURA
or view top-rated stocks among Wall Street analysts.

How have AURA shares performed in 2024?

Aura Biosciences' stock was trading at $8.86 at the beginning of the year. Since then, AURA stock has decreased by 13.1% and is now trading at $7.70.
View the best growth stocks for 2024 here
.

How were Aura Biosciences' earnings last quarter?

Aura Biosciences, Inc. (NASDAQ:AURA) released its quarterly earnings data on Wednesday, March, 15th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.06.

What ETFs hold Aura Biosciences' stock?

ETFs with the largest weight of Aura Biosciences (NASDAQ:AURA) stock in their portfolio include AltShares Event-Driven ET (EVNT).Range Cancer Therapeutics ETF (CNCR).

When did Aura Biosciences IPO?

Aura Biosciences (AURA) raised $81 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 5,400,000 shares at $14.00-$16.00 per share.

Who are Aura Biosciences' major shareholders?

Aura Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Matrix Capital Management Company LP (18.09%), Eventide Asset Management LLC (15.17%), Vanguard Group Inc. (4.52%), Vanguard Group Inc. (4.52%), Nantahala Capital Management LLC (3.45%) and Goldman Sachs Group Inc. (2.71%). Insiders that own company stock include Cadmus Rich, David Michael Johnson, Julie B Feder, Los Pinos Elisabet De, Matrix Capital Management Comp and Rosch Mark De.
View institutional ownership trends
.

How do I buy shares of Aura Biosciences?

Shares of AURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AURA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners